Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/178631
Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
There are few published data on long-term treatment with sirolimus in lymphangioleiomyomatosis (LAM). The objective of this study was to describe the long-term effect of sirolimus in a series of LAM patients followed up in a referral centre, focusing on pulmonary function. We retrospectively reviewed a series of 48 patients with LAM diagnosed, followed up and treated with sirolimus in a single centre. Response to sirolimus was evaluated at 1 and 5 years. A negative sirolimus response was defined as an FEV1 decline greater than - 75 ml/year. A mixed-effects model was used to estimate the longitudinal changes in FEV1 (average slope), both as absolute (ml/year) and as predicted values (%predicted/year). From a total of 48 patients, 9 patients underwent lung transplantation and 4 died during the study. Mean (95% CI) FEV1 slope over 5 years was - 0.14 (- 26.13 to 25.85) ml/year in the whole LAM group, 42.55 (14.87 to 70.22) ml/year in the responder group, - 54.00 (- 71.60 to - 36.39) ml/year in the partial responder group and - 84.19 (- 113.5 to - 54.0) ml/year in the non-responder group. After 5 years of sirolimus treatment 59% had a positive response, 30% had a partial response and 11% had a negative response. Our study found that sirolimus treatment had a positive long-term effect on most LAM patients.
Matèries
Matèries (anglès)
Citació
Citació
REVILLA LÓPEZ, Eva, BERASTEGUI, Cristina, MÉNDEZ, Alejandra, SÁEZ GIMÉNEZ, Berta, RUIZ DE MIGUEL, Victoria, LÓPEZ MESEGUER, Manuel, MONFORTE, Victor, BRAVO, Carlos, PUJANA GENESTAR, M. ángel, RAMON, Maria antonia, GÓMEZ OLLÉS, Susana, ROMAN, Antonio, Vall d’Hebron Multidisciplinary Cystic Lung Disease Group. Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience. _Scientific Reports_. 2021. Vol. 11. [consulta: 26 de febrer de 2026]. [Disponible a: https://hdl.handle.net/2445/178631]